Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3327388
Max Phase: Preclinical
Molecular Formula: C23H30N2O6
Molecular Weight: 430.50
Molecule Type: Small molecule
Associated Items:
ID: ALA3327388
Max Phase: Preclinical
Molecular Formula: C23H30N2O6
Molecular Weight: 430.50
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1cc([C@H](CC=C(C)C)OC(=O)CC(C)C)c(OC)c2c1/C(=N/O)C=C/C2=N\O
Standard InChI: InChI=1S/C23H30N2O6/c1-13(2)7-10-18(31-20(26)11-14(3)4)15-12-19(29-5)21-16(24-27)8-9-17(25-28)22(21)23(15)30-6/h7-9,12,14,18,27-28H,10-11H2,1-6H3/b24-16+,25-17+/t18-/m0/s1
Standard InChI Key: KSNHMNQDRBNSEV-IMSPSDRLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 430.50 | Molecular Weight (Monoisotopic): 430.2104 | AlogP: 4.62 | #Rotatable Bonds: 8 |
Polar Surface Area: 109.94 | Molecular Species: ACID | HBA: 8 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 5.02 | CX Basic pKa: | CX LogP: 4.01 | CX LogD: 1.77 |
Aromatic Rings: 1 | Heavy Atoms: 31 | QED Weighted: 0.27 | Np Likeness Score: 1.01 |
1. Wang R, Zhang X, Song H, Zhou S, Li S.. (2014) Synthesis and evaluation of novel alkannin and shikonin oxime derivatives as potent antitumor agents., 24 (17): [PMID:25127868] [10.1016/j.bmcl.2014.07.012] |
2. Stallinger A, Kretschmer N, Kleinegger F, Brvar L, Liegl-Atzwanger B, Prokesch A, Durchschein C, Bauer R, Deutsch A, Rinner B.. (2020) β,β-Dimethylacrylshikonin Induces Apoptosis in Melanoma Cell Lines by NOXA Upregulation., 83 (2): [PMID:31961147] [10.1021/acs.jnatprod.9b00719] |
3. Valipour M.. (2022) Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action., 235 [PMID:35367708] [10.1016/j.ejmech.2022.114314] |
Source(1):